Last updated: February 17, 2026
Overview
NDC 10370-0280 corresponds to Nivestim, a biosimilar resembling filgrastim used primarily in treating neutropenia caused by chemotherapy. As of 2023, Nivestim has gained approval in various markets, including the U.S. and Europe, mainly through regulatory pathways that facilitate biosimilars’ entry to improve treatment access and control costs.
Market Position and Adoption
Nivestim has faced competitive pressures from established filgrastim biosimilars, such as Amgen’s Neupogen and Sandoz’s Zarxio, among others. The biosimilar market generally goals to reduce treatment costs through price competition, which influences adoption rates.
In the U.S., biosimilar market penetration remains gradual due to formulary preferences, prescriber inertia, and reimbursement policies. In Europe, rapid adoption follows more flexible regulatory environments and price negotiations. The global market for filgrastim biosimilars was valued at approximately $3.5 billion in 2022 and is projected to grow at a CAGR of around 8–10% over the next five years, driven by healthcare cost containment policies and expanded indications.
Pricing Dynamics
- Brand-name filgrastim (Neupogen): Historically priced around $8,000–$12,000 per treatment cycle, depending on dosage and region.
- Biosimilar Nivestim: Launched at prices 20-35% lower than the originator, typically around $5,000–$8,000 per cycle initially. Over time, biosimilar prices tend to decrease further, sometimes by an additional 15-25%, driven by market competition.
| Price Projections (2023–2028) |
Year |
Estimated Average Price per Cycle |
Notes |
| 2023 |
$4,500–$7,000 |
Initial sell price in most markets, with some reductions driven by payers. |
| 2024 |
$4,200–$6,500 |
Slight price decrease as formulary barriers improve, with increased biosimilar uptake. |
| 2025 |
$4,000–$6,000 |
Price stabilization; broader payer discounts. |
| 2026 |
$3,800–$5,500 |
Continued market penetration reduces prices further. |
| 2027 |
$3,500–$5,000 |
Competitive pressure from additional biosimilars. |
| 2028 |
$3,200–$4,500 |
Potential for further discounts, contingent on market dynamics. |
Market Drivers and Constraints
- Regulatory environment: Faster approval and substitution policies in Europe boost biosimilar uptake.
- Payer policies: Favor formulary inclusion of biosimilars, leading to negotiated discounts.
- Physician acceptance: Cultural shifts and clinical data favor biosimilar substitution.
- Patent litigation and exclusivity: Ongoing patent challenges might influence launch timelines and pricing strategies.
| Key Competitive Landscape |
Product |
Manufacturer |
Year Approved |
Price Range (2023) |
Market Share (Estimated) |
| Neupogen |
Amgen |
1991 |
$8,000–$12,000 |
50% (originator) |
| Zarxio |
Sandoz |
2015 |
$5,000–$8,000 |
20–25% (biosimilar) |
| Nivestim |
Biocon / Mylan |
2016 |
$4,500–$7,000 |
10–15% (biosimilar) |
Regulatory and Reimbursement Considerations
- United States: Biosimilar substitution remains limited by FDA and CMS policies; cluster guidance influences pricing.
- Europe: National reimbursement negotiations allow for significant price reductions, accelerating biosimilar integration.
- Emerging Markets: Price elasticity is high; biosimilars like Nivestim could achieve broader access at lower prices.
Summary
Nivestim’s market prospects hinge on biosimilar acceptance, competitive pricing, and payer policies. Price projections show continued decline over the next five years due to increasing market penetration and competitive forces. The trajectory depends on regulatory reforms and clinical acceptance, with potential for further discounts if biosimilar competition intensifies.
Key Takeaways
- Nivestim faces higher market entry barriers in the U.S. but benefits from rapid adoption in Europe.
- Prices are expected to decline steadily, with biosimilar competition shaping costs.
- The global market for filgrastim biosimilars is poised for growth, reaching over $6 billion by 2027.
- Reimbursement policies and regulatory environments significantly influence market share and pricing.
- Cost reductions will continue as biosimilar manufacturers enhance market penetration.
Frequently Asked Questions
1. How does the pricing of Nivestim compare globally?
Prices in Europe tend to be lower due to national negotiations, sometimes by 30–40% compared to the U.S. Since launch, it has been priced around 20–35% below originator prices, with further decreases expected.
2. What factors influence biosimilar adoption in the U.S.?
Regulatory policies, payers' formulary decisions, and physician acceptance influence uptake. Barriers include limited automatic substitution and market entry timing.
3. How will regulatory changes impact Nivestim’s market?
Streamlined biosimilar approval pathways and substitution laws could accelerate market share gains, potentially further lowering prices.
4. Are there any major patent litigations affecting Nivestim’s market?
Patent litigation can delay biosimilar market entry; Nivestim’s manufacturer has faced patent disputes but has generally maintained market presence post-approval.
5. What are the main competitive threats to Nivestim?
Established biosimilars like Zarxio and upcoming entrants with similar or superior clinical data might exert pricing pressure or limit market share expansion.
References
- IQVIA. "Global Biosimilar Market Report 2022."
- FDA. "Guidance for Industry—Biosimilar Product Information," 2020.
- European Medicines Agency. "Biosimilars: What you need to know," 2022.
- Evaluate Pharma. "Market Analysis and Forecast Data," 2023.
- CMS. "Medicare Part B Drug Pricing Policies," 2022.
